logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls/Updates
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
    • 08 SEP 2021

    PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

    LAGUNA HILLS, CA, September 8, 2021 (BUSINESS WIRE) – PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference to be held

    Read more →
    • Posted in
    • News
    • 31 AUG 2021

    PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study

    LAGUNA HILLS, CA, August 31, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its clinical trial product, CypCaps™, remains stable and active at 18 months after completing the 18-month timepoint of ongoing

    Read more →
    • Posted in
    • News
    • 25 AUG 2021

    PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

    LAGUNA HILLS, CA, August 25, 2021 (BUSINESS WIRE)—PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Company will expand its product pipeline to again include its diabetes program and its malignant ascites program.

    Read more →
    • Posted in
    • News
    • 23 AUG 2021

    PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules, of 14,000,000 shares of the Company’s common stock

    Read more →
    • Posted in
    • News
    • 19 AUG 2021

    PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    LAGUNA HILLS, CA, August 19, 2021 (BUSINESS WIRE)—PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale, in a registered direct

    Read more →
    • Posted in
    • News
    • 16 AUG 2021

    PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus

    LAGUNA HILLS, CA, August 16, 2021 (BUSINESS WIRE)—PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today released a statement from Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, regarding the Company’s recent listing on Nasdaq

    Read more →
    • Posted in
    • News
    • 12 AUG 2021

    PharmaCyte Biotech Announces Closing of $15-Million Public Offering

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the closing of its previously announced underwritten public offering of approximately $15 million. The public offering includes 3,529,412 shares of the Company’s

    Read more →
    • Posted in
    • News
    • 09 AUG 2021

    PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Company’s common stock is expected to begin trading on The Nasdaq Capital Market on August 10, 2021, under the symbol

    Read more →
    • Posted in
    • News
    • 02 AUG 2021

    PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCBD) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that The Nasdaq Stock Market LLC (Nasdaq) has approved the listing of the Company’s common stock on Nasdaq. The Company’s common stock

    Read more →
    • Posted in
    • News
    • 22 JUL 2021

    PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment

    LAGUNA HILLS, CA, July 22, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCBD), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that three independent industry publications mention PharmaCyte and/or its past clinical trials and their contributions to prior and future work

    Read more →
    • Posted in
    • News
  • «
  • ‹
  • 2
  • 3
  • 4
  • 5
  • 6
  • ›
  • »